3.7% of patients with one or both risk factors bled, 0.2% of patients without either of them bled. When SUP is used, we suggest the use of proton pump inhibitors rather than H2 receptor antagonists (Grade 2C).
3.7% of patients with one or both risk factors bled, 0.2% of patients without either of them bled. When SUP is used, we suggest the use of proton pump inhibitors rather than H2 receptor antagonists (Grade 2C).
3.7% of patients with one or both risk factors bled, 0.2% of patients without either of them bled. When SUP is used, we suggest the use of proton pump inhibitors rather than H2 receptor antagonists (Grade 2C).
We recommend that stress ulcer prophylaxis using H2 blocker or proton pump inhibitor be given to patients with severe sepsis/septic shock who have bleeding risk factors (Grade 1B). We suggest that patients without risk factors should not receive prophylaxis (Grade 2B).
Slide 2 Copyright 2014 SCCM/ESICM
3.7% of patients with one or both risk factors bled, <0.2% of
patients without either of them bled. Cook et al. N Engl J Med. 1994;330:377-381 Slide 3 Copyright 2014 SCCM/ESICM
How Frequent Is Clinically Important
Bleeding? Can We Prevent It with H2RA?
Marik et al. Crit Care Med. 2010;38:2222-2228
Slide 4 Copyright 2014 SCCM/ESICM
Dellinger et al. Crit Care Med. 2013;41:580637
Dellinger et al. Intensive Care Med. 2013;39:165-228 Slide 5 Copyright 2014 SCCM/ESICM
Stress Ulcer Prophylaxis
When stress ulcer prophylaxis is used, we suggest the use of proton pump inhibitors rather than H2 receptor antagonists (Grade 2C).
Slide 6 Copyright 2014 SCCM/ESICM
Do We Have Options Other Than
H2RA?
Alhazzani et al. Crit Care Med. 2013;41:693-705
Slide 7 Copyright 2014 SCCM/ESICM
Dellinger et al. Crit Care Med. 2013;41:580637
Dellinger et al. Intensive Care Med. 2013;39:165-228 Slide 8 Copyright 2014 SCCM/ESICM
We recommend that stress ulcer prophylaxis
using H2RA or PPI be given to patients with severe sepsis/septic shock who have bleeding risk factors (Grade 1B). When SUP is used, we suggest the use of PPI rather than H2RA (Grade 2C). We suggest that patients without risk factors should not receive prophylaxis (Grade 2B).